Martin Shkreli is an American former hedge fund manager and convicted felon.
Shkreli is the co-founder of the hedge funds;
- Elea Capital,
- MSMB Capital Management and
- MSMB Healthcare; the co-founder and former chief executive officer (CEO) of the pharmaceutical firms Retrophin and Turing Pharmaceuticals (now Vyera Pharmaceuticals); and the former CEO of start-up software company Gödel Systems, which he founded in August 2016.
In September 2015, Shkreli was widely criticized when Turing obtained the manufacturing license for the antiparasitic drug Daraprim and raised its price from US$13.50 to $750 per pill.
Christie Smythe, a former reporter for Bloomberg News broke the news of Shkreli’s arrest in 2015.
In 2017, Shkreli was charged and convicted in federal court on two counts of securities fraud and one count of conspiring to commit securities fraud, unrelated to the Daraprim controversy.
Shkreli was sentenced to seven years in federal prison and up to $7.4 million in fines and in the civil case, he was fined a further $64.6 million to be given to victims nationwide.
In 2020, Smythe revealed that she was in a relationship with Shkreli.
Apparently, Smythe, a former rising Bloomberg journalist quit her job and divorced her husband to pursue a doomed relationship with Shkreli.
However, Shkreli broke up with her through his lawyers when she sensationally went public with the relationship in a 2020 Elle magazine feature.
Prior to May 2022, Shkreli was held at the low-security federal prison in Allenwood, Pennsylvania, with an expected release date in September 2022.
On May 18, 2022, it was announced that Shkreli had been released early.
As of now, Shkreli is not married.